PLG and myeloid sarcoma: A preliminary investigation was conducted to characterize the role of IgG antibodies against seven coagulant components, i.e., FVIIa, thrombin, prothrombin, FXa, FXII, plasmin, and protein C, and to determine whether these molecules could potentially serve as pro-inflammatory biomarkers in MS pathology.